SAN FRANCISCO — A low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children aged 3 to 17 years, according to phase 3 data presented here.
“Over 3 years, NVK002 0.01% meaningfully slowed myopia progression at 0.5 D, 0.75 D and 1 D thresholds,” Darren J. Bell, MD, said at the American Academy of Ophthalmology meeting.
Bell reported results from the phase 3 CHAMP clinical study, which evaluated children with –0.5 D to –6 D spherical equivalent refraction. Participants were randomly assigned to receive either placebo or